Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24756014 | 1.00 | CA1 (0.70) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL17545919 | 0.93 | CA1 (0.71) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL27694125 | 0.89 | CA1 (0.62) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL28767041 | 0.89 | CA1 (0.62) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL2897115 | 0.89 | CA1 (0.62) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL3467616 | 0.88 | CA1 (0.65) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL3487968 | 0.87 | CA1 (0.71) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL1159172 | 0.87 | CA1 (0.71) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL3487489 | 0.87 | CA1 (0.71) | CA1CA2HSD11B1CYP2C9CTSK | |
| SCHEMBL1467769 | 0.87 | CA1 (0.71) | CA1CA2HSD11B1CYP2C9CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-106188027-B | Aromatic heterocyclic derivative and application thereof in medicine | 广东东阳光药业有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | CA1 4688/4885CA2 3198/4885HSD11B1 72/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | CA1 4688/4885CA2 3198/4885HSD11B1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.